Skip to main content
. 2021 Apr 19;11:654350. doi: 10.3389/fonc.2021.654350

Figure 6.

Figure 6

Validation of the prognostic value of CD86 for LGG in CGGA. (A) Kaplan-Meier analysis of CD86 expression and OS in all LGG. (B) Kaplan-Meier analysis of CD86 expression and OS in primary LGG. (C) Kaplan-Meier analysis of CD86 expression and OS in recurrent LGG. (D) Univariate Cox regression of CD86 expression, LGG cancer type (primary or recurrent), grade, gender and age. (E) Multivariate Cox regression using the same variables.